Study Evaluating TTI-237 in Advanced Malignant Solid Tumors

This study has been terminated.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00195247
First received: September 12, 2005
Last updated: March 22, 2007
Last verified: March 2007
  Purpose

The purpose of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.


Condition Intervention Phase
Neoplasms
Drug: TTI-237
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1 Dose Escalation Study of TTI-237 Administered Intravenously Every 3 Weeks in Subjects With Advanced Malignant Solid Tumors

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Primary purpose is to address the safety and tolerability of TTI-237. Patient will be assessed on an ongoing basis during their participation on the trial.

Secondary Outcome Measures:
  • Preliminary pharmacokinetics (cycle 1 only) and anti-tumor activity of TTI-237 (approximately every 8 weeks).

Estimated Enrollment: 45
Study Start Date: May 2005
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented diagnosis of malignant solid tumor with measurable disease
  • Life expectancy of at least 12 weeks
  • ECOG performance status of 0, 1, or 2

Exclusion Criteria:

  • Recent major surgery, radiation therapy or anti-cancer treatment
  • History of any other prior malignancy within the last 5 years
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00195247

Locations
United States, Arizona
Scottsdale, Arizona, United States, 85016
United States, California
Los Angeles, California, United States, 90095
United States, Maryland
Baltimore, Maryland, United States, 21231
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00195247     History of Changes
Obsolete Identifiers: NCT00112814
Other Study ID Numbers: 3162K1-101
Study First Received: September 12, 2005
Last Updated: March 22, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Tumors
Advanced malignant solid tumors

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on April 17, 2014